GLP toxicology testing and phase 2/3 development for a nonopioid, injectable drug product for the treatment of lumbosacral radiculopathy (sciatica)
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110425
- Recipient
-
Spinethera Inc. UEI GBWBLWKNCHY5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $4,970,751
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Originally
- Place of performance
- Minneapolis, MN 55447, USA
Award details come from USAspending.gov.
About this award
Spinethera Inc. was awarded a $4,970,750.90 Project Grant from the Defense Health Agency to conduct GLP toxicology testing and Phase 2/3 development for a nonopioid, injectable drug product for the treatment of lumbosacral radiculopathy, also known as sciatica. This work will be carried out under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative and impactful investigations. Specifically, the agency aims to develop medical solutions for battlefield conditions. The total period of performance for this award is from June 1, 2021 through November 30, 2023 in Minneapolis, Minnesota.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $4,970,751 |
Quick answers
Who received award W81XWH2110425?
W81XWH2110425 was awarded to Spinethera Inc. by Defense Health Agency (Department of Defense) on June 1, 2021.
How much is award W81XWH2110425 worth?
$4,970,751 has been obligated on W81XWH2110425.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award